knowledge -WSS

knowledge

author：fashion 2025-09-29 20:00:18 - browse：194

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Pancreatic cancer is often deadly, but new discoveries are raising hope

WSS

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Young boy dies in trial for Pfizer Duchenne gene therapy

California man arrested in connection with serial murders of Mexican strip club workers

Insurer loopholes limit power of law against surprise medical bills

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

Titanic submersible victims' family mourns: 'Enormous tragedy and devastation'

entertainment

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Hepatitis C has a cure — but many Americans still lack access to it

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

In age of alternative facts, a scholarly course on calling out crap

With fresh data, a dynamic duo powers Eli Lilly to new heights

Virginia high school admissions case could be legal follow

Republican states more likely to report Covid vaccine side effects

At least 13 dead in Texas as scorching temps continue

Alzheimer's risk factor APOE4 may be a distinct form of the disease

In Memoriam: Notable people who died in 2023

Oral obesity drug from Viking Therapeutics hits key early target

focus

Titanic submersible victims' family mourns: 'Enormous tragedy and devastation'

Scientists uncover potential path to treating deadly childhood tumor

Drug companies' payments and gifts affect physicians' prescribing

Medicare Advantage 2025 payments will dip, Biden administration says

Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

UnitedHealth, in a surprise, takes aim at Steward’s physician group

entertainment

knowledge

leisure time

hotspot